ICER assesses GSK's Nucala, Novo's Tresiba

The Institute for Clinical and Economic Review said the annual value-based price of asthma therapy Nucala mepolizumab from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) should be $7,787-$12,116 based on variable cost-effectiveness thresholds. The price range would represent a 63-76% discount to Nucala's list price of $32,500 per year.

ICER based the lower value-based price on a quality-adjusted life year (QALY) of $100,000, and the higher price on a QALY of $150,000. The institute said there was "moderate certainty" that adding Nucala to inhaled corticosteroids or other standard of care treatments led to comparable or better health benefits, but said Nucala's long-term benefit has not yet been demonstrated due to the small size and short duration of pivotal trials of the drug, as well as potential harm from immune modulation. ...